Omda AS (OSL:OMDA)
Norway
· Delayed Price · Currency is NOK | Market Cap | 842.86M |
| Revenue (ttm) | 495.69M |
| Net Income (ttm) | 6.61M |
| Shares Out | 20.51M |
| EPS (ttm) | 0.32 |
| PE Ratio | 127.55 |
| Forward PE | 13.98 |
| Dividend | 0.47 (1.15%) |
| Ex-Dividend Date | n/a |
| Volume | 409 |
| Average Volume | 5,462 |
| Open | 40.00 |
| Previous Close | 40.70 |
| Day's Range | 39.60 - 41.10 |
| 52-Week Range | 37.00 - 57.40 |
| Beta | 0.42 |
| RSI | 55.67 |
| Earnings Date | Apr 10, 2026 |
About Omda AS
Omda AS provides software solutions for the healthcare and emergency response sector in Norway, Sweden, Denmark, Finland, and internationally. The company offers laboratory information management systems consisting of Omda ProSang, a blood, cell, and tissue management system; and medical medication solution comprising Omda Cytodose, an oncology medication management solution. It also provides connected healthcare solutions, including Omda Cardio, an ECG and diagnostic storage tool; Omda CIMA, a clinical imaging mobile application; Omda Media, a... [Read more]
Financial Performance
Financial StatementsNews
Omda AS (FRA:6Q1) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Amidst ...
Omda AS (FRA:6Q1) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Amidst Challenges
Omda AS Earnings Call Transcript: Q4 2025
Record revenue and EBITDA achieved in 2025, with strong recurring revenue and improved margins. AI now central to operations, driving efficiency, and 2026 guidance targets further growth and margin expansion. Active M&A pipeline and refinancing options support future ambitions.
Omda AS (FRA:6Q1) Q3 2025 Earnings Call Highlights: Record-High EBITDA Margin and Strong ...
Omda AS (FRA:6Q1) Q3 2025 Earnings Call Highlights: Record-High EBITDA Margin and Strong Revenue Growth
Omda AS Earnings Call Transcript: Q3 2025
Record 30% EBITDA margin and 14% revenue growth highlight a strong quarter, with recurring revenue at 94% and robust guidance for 2025–2026. M&A remains a key growth lever, with efficiency gains and margin expansion targeted.
Omda AS (FRA:6Q1) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Milestones
Omda AS (FRA:6Q1) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Milestones
Omda AS Earnings Call Transcript: Q2 2025
Strong Q2 results with 16% revenue growth, record recurring revenues, and EBITDA margin more than doubling year-over-year. Guidance for 2025 and 2026 is reaffirmed, with continued focus on organic and inorganic growth, cost efficiency, and prudent M&A.
Omda AS Earnings Call Transcript: Q1 2025
Q1 delivered 15% revenue growth and a record NOK 93 million in recurring revenue, with EBITDA margin rising to 22%. Guidance for 2025 and 2026 remains unchanged, supported by strong recurring income and recent acquisitions.
Omda AS Earnings Call Transcript: Q4 2024
Record revenue and recurring income marked Q4 2024, with restructuring completed and strong cash discipline achieved. 2025 guidance targets NOK 460–485 million revenue and higher EBITDA margins, driven by organic growth and operational leverage.
Omda AS Transcript: Status Update
Three acquisitions—Predicare, Averia, and Dermicus—expand the emergency and imaging software portfolio, with integration expected to be smooth and margin expansion secured through cost reductions. Cash flow and working capital improvements support continued M&A and a 30% EBITDA margin target by late 2025.
Omda AS Earnings Call Transcript: Q3 2024
Q3 2024 saw NOK 103 million in income, 21% EBITDA margin, and 6% recurring revenue growth. All business areas except Emergency performed well; cost reductions and decentralization are expected to improve margins in coming quarters.
Omda AS Earnings Call Transcript: Q2 2024
Organic growth reached 5.4% in Q2 2024, with recurring revenues strong and low churn. EBITDA was flat year-over-year, impacted by high personnel costs and weak professional services, but cost-saving and productivity initiatives are underway. Margin improvement and further M&A remain key priorities.